MYH9

Across TCGA pan-cancer cohorts, MYH9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYH9 data layer compared with 23 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MYH9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYH9 expression acts as an unfavorable survival marker.

LSCC, PDAC, and LUAD are the cancer types where MYH9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.482	0.798	.017	15	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	12	view →
LUAD	OS	Tertile	All	0.765	0.935	.012	6	view →
GBM	DFS	Tertile	All	0.258	0.450	.014	4	view →
HNSC	OS	Median	IV	0.613	0.822	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MYH9–LSCC (DFS)

Open the LSCC breakdown →